AbCellera Biologics Inc. (ABCL)
NASDAQ: ABCL · Real-Time Price · USD
3.565
-0.055 (-1.52%)
Nov 26, 2025, 12:06 PM EST - Market open

AbCellera Biologics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2024FY 2023FY 2022FY 2021FY 20202018 - 2019
Period Ending
Nov '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
1,0678651,6572,8984,02710,832
Upgrade
Market Cap Growth
33.81%-47.77%-42.83%-28.02%-62.83%-
Upgrade
Enterprise Value
7302949522,1063,30510,829
Upgrade
Last Close Price
3.622.935.7110.1314.3040.24
Upgrade
PE Ratio
---18.2826.24127.29
Upgrade
Forward PE
----51.81-
Upgrade
PS Ratio
30.5030.0243.575.9710.7346.46
Upgrade
PB Ratio
1.110.821.442.353.9313.04
Upgrade
P/TBV Ratio
1.240.901.682.754.8515.84
Upgrade
P/FCF Ratio
---14.0221.63832.15
Upgrade
P/OCF Ratio
---10.4516.46477.40
Upgrade
EV/Sales Ratio
20.6710.1925.034.348.8146.45
Upgrade
EV/EBITDA Ratio
---8.6215.1067.32
Upgrade
EV/EBIT Ratio
---9.3616.1769.40
Upgrade
EV/FCF Ratio
---10.1917.76831.92
Upgrade
Debt / Equity Ratio
0.150.060.070.070.040.01
Upgrade
Debt / EBITDA Ratio
---0.320.180.03
Upgrade
Debt / FCF Ratio
---0.400.220.34
Upgrade
Asset Turnover
0.030.020.030.340.320.45
Upgrade
Inventory Turnover
---108.8169.8671.97
Upgrade
Quick Ratio
8.498.956.938.377.447.81
Upgrade
Current Ratio
10.109.817.338.677.717.86
Upgrade
Return on Equity (ROE)
-16.81%-14.75%-12.27%14.03%16.54%28.29%
Upgrade
Return on Assets (ROA)
-10.43%-12.41%-9.79%9.83%10.99%18.95%
Upgrade
Return on Capital (ROIC)
-12.71%-15.03%-11.65%11.81%13.44%22.89%
Upgrade
Return on Capital Employed (ROCE)
-17.80%-22.00%-17.30%15.80%17.10%17.30%
Upgrade
Earnings Yield
-15.84%-18.82%-8.84%5.47%3.81%1.10%
Upgrade
FCF Yield
-14.13%-21.60%-7.29%7.13%4.62%0.12%
Upgrade
Buyback Yield / Dilution
-1.57%-1.79%8.15%1.09%-20.96%-73.88%
Upgrade
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q